Sysnav Healthcare Announces Multi-Year Partnership with Roche Based on Sysnav’s Proprietary Motion Tracking Technology

Vernon, France, January 25, 2023 /PRNewswire/ — Sysnav Healthcare and Roche enter into partnership to facilitate the development of industry-standard outcome measures for disorders related to movement disorders, as well as the design of next-generation wearable technologies based on Sysnav’s unique technology.

Patients with neuromuscular disorders often experience movement impairments that fundamentally affect their daily lives. Reliable, objective measurements of changes in a patient’s motor function can help physicians prescribe the most appropriate treatment options and support research aimed at developing new drugs that improve lives. Sysnav Healthcare develops medical-grade wearables based on magnetic-inertial technology for 3D motion reconstruction. This enables precise motion tracking without GPS, enabling indoor monitoring while preserving patient privacy. Sysnav has worked closely with academic collaborators, patient associations and Roche to obtain first-ever European Medicines Agency qualification for a digital endpoint (SV95c) for Duchenne muscular dystrophy.

Sysnav Healthcare and Roche have expanded their collaboration across multiple projects to develop meaningful digital endpoints that will monitor disease progression, support clinical trials and serve as regulator-approved outcome measures. The partnership will also develop next-generation wearable technology to further advance personalized healthcare. “Sysnav’s technology provides the opportunity to measure the progression of functional disease to a range of disease regulatory criteria. This has the potential to improve the way patients participate in clinical research, the ability to identify potential therapeutic benefits, and enrich our understanding of disease pathophysiology,” Say james sabriGlobal Head of Roche Pharma Partnering.

When high-precision technology meets clinical expertise, it’s a game-changing combination that can accelerate medical progress.Combining Sysnav’s digital health technology with Roche’s expertise in neuroscience drug development and personalized healthcare will allow us to make a real and meaningful impact on people with movement disorders. By establishing a new set of industry standards for sports injury assessment, we can unlock innovation for the benefit of all patients,said Damien Eggenspieler, Director of Healthcare Programs at Sysnav.

About Sysnav Healthcare

Sysnav Healthcare is the leading business unit of Sysnav, a fast-growing French independent technology company. Since the beginning of the event, Sysnav Healthcare has aimed to unlock the potential of real data in the medical field by adopting extremely accurate motion capture solutions to meet the needs of healthcare professionals and patients. The company has developed two wearable devices: ActiMyo® and Syde®, and is the first ever EMA-certified digital endpoint (SV95c). Sysnav Healthcare, a pioneer and leader in exercise assessment in clinical trials, is building the next generation of digital health technology so patients can benefit from life-changing treatments earlier and more reliably.

For more information, please visit:



View the original content: 301729991.html

SOURCESysnav Healthcare

Source link